Ph 3 INTerpath-001 Trial of Intismeran Autogene + KEYTRUDA Met RFS and DMFS Endpoints in Patients With Completely Resected Stage IIB-IV Melanoma August 25, 2026
Zipalertinib + Chemo Meet Primary PFS Endpoint in Planned Interim Analysis of Ph 3 REZILIENT3 Trial in 1L EGFR Exon 20 Insertion Mutation NSCLC August 20, 2026
Enhertu demonstrated statistically significant and clinically meaningful PFS improvement in HER2-mutant NSCLC in DESTINY-Lung04 Ph 3 trial August 20, 2026
Final ASTRUM-002 Analysis Shows Survival Benefit with Hetronifly in Advanced non squamous NSCLC After Four Years of Follow-Up August 20, 2026
FAILED TRIAL: Ph 2 DeFianCe study of sirexatamab (DKN-01) in 2L CRC did not meet primary endpoint of PFS improvement August 20, 2026
Positive Topline Ph 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma Reported August 20, 2026
ORPATHYS + TAGRISSO Demonstrated Statistically Significant PFS/OS Improvements in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO August 20, 2026
Topline Results from Intranasal NEO100 in Recurrent IDH1-mutant High-grade Glioma to be presented August 11, 2026
FAILED TRIAL: Ph 3 XPORT-EC-042 Trial of Selinexor in Endometrial Cancer Did Not Meet the Primary Endpoint of PFS improvement August 5, 2026
MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients August 5, 2026
Positive Updated Ph 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma Announced July 28, 2026
TECVAYLI + TALVEY reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line R/R multiple myeloma July 28, 2026
Sonesitatug vedotin demonstrated statistically significant OS improvement in 2L+ CLDN18.2-positive advanced gastric/GEJ cancers July 28, 2026
Confirmed Durable Partial Response in Ph 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy July 28, 2026
FAILED TRIAL: Ph 3 EPCORE® DLBCL-1 Trial of Epcoritamab in Patients with R/R DLBCL failed to meet primary OS endpoint July 28, 2026
Encouraging First OS Data from 1L Higher-Risk (HR) MDS Patients in the BEXMAB Ph 1/2 Trial Announced July 28, 2026
Ph 2 data show EO2463-induced CD8 T-cell expansion correlates with PFS in patients with indolent NHL in the watch-and-wait setting July 28, 2026
Preliminary data from Ph 2 MRD translational clinical trial of IMNN-001 + SOC N/ACT & bevacizumab in women with 1L advanced ovarian cancer announced July 28, 2026
Positive Data Demonstrating 100% ORR and 18.2-Month Median OS with Alpha DaRT + Pembrolizumab combo in Locally Advanced or Metastatic Head and Neck Cancer Reported July 28, 2026
Durable Clinical Activity of Darlifarnib + Cabozantinib Reported in Cabozantinib-Naïve Clear Cell RCC Patients July 28, 2026
Ivonescimab + Chemo Shows Consistent, Favorable OS Results in Western and Asian Patients in Updated Analysis from Global Ph 3 HARMONi Study July 28, 2026
Interim Safety Data in Ph 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients Reported July 22, 2026
Ph 3 Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as 1L PD-L1-Neg Non-Squamous NSCLC Met Primary Endpoint July 22, 2026
KEYTRUDA Monotherapy Significantly Improved PFS vs chemo in Certain Patients With Advanced or Recurrent MMR-deficient Endometrial Cancer July 22, 2026
